Lowest Price Guaranteed From USD 2,499
Published
January 2017
Pages
365
View Count
5862
Example Insights
An updated edition is available at the following link
Report Description
Drug delivery systems optimized to provide flexibility in dosing regimen, reduce the number of hospital visits, decrease dependence on healthcare professionals and enhance adherence to the therapeutic regimen have become the preferred choice of drug administration. The large scale adoption of prefilled syringes, the first ready-to-use injection device to be marketed, demonstrated the growing interest in the concept of such convenient drug delivery systems. In addition, several pen-injectors and autoinjectors have witnessed an impressive growth in the recent past. However, these hand-held devices are only capable of administering drugs with dosing volume close to 1 ml. With over 900 biologics being developed (most of these are highly viscous and are required to be delivered in volumes greater than 1 ml), there is a growing demand for self-administration devices than can overcome this unmet need.
Large volume wearable injectors, an advanced version of the existing self-injection devices, are expected to gather interest from a wide customer base. In fact, there are a number of such injectors commercially available for delivery of insulin. OmniPod, from Insulet Corporation, is a very well-known device that has generated significant year-on-year revenue growth. However, it is worth highlighting that till date only a few large volume wearable injectors (for instance, Amgen . Insulet Corporation's OnProTM and West Pharmaceutical's SmartDose Electronic Wearable Injector) have been approved for the administration of a non-insulin biologic. Despite the uncertainties related to the device development and approval, many companies are investing their time, money and resources to develop these novel devices. In addition to the publically known programs, pharma companies have many undisclosed programs that are likely to provide the necessary growth impetus in the long term.
It is worth noting that the VC community has demonstrated significant interest in funding projects related to such wearable injectors. These investments are expected to drive further innovation and lead to the introduction of novel device candidates in the industry. Quite recently, in January 2017, scPharmaceuticals closed a series B investment round worth USD 45.6 million. The company intends to use the funding to bring Furoscix and the sc2Wear Infusor to the market in the US. Earlier, in July 2016, SteadyMed Therapeutics raised USD 32 million in a private placement round financed by Deerfield Capital Management, Federated Investors and OrbiMed. In September 2015, CeQur completed a USD 100 million Venture (Series C) financing round, which was led by Woodford Investment Management, Arthurian Life Sciences, Endeavour Vision, VI Partners and Schroders.
Several partnerships have also been inked in this domain in the last few years. Most of these are focused on the development / commercialization of a variety of wearable injectors. Such partnerships are important for technological integration, supply of devices and also facilitate the conduct of clinical trials related to drug-device combination products. We believe that the device developers will continue to strive to introduce unique and user-friendly features into their proprietary range of devices. The upgradation of existing devices to more competent / next generation devices will serve as a key driver of immediate near-term growth.
Scope of the Report
The “Large Volume Wearable Injectors Market (3rd Edition), 2017-2027” report features an extensive study of the current landscape and the likely future evolution of this category of drug delivery devices over the next ten years. With the increasing incidence of chronic and lifestyle-related diseases across the globe, the demand for efficient drug delivery systems is growing at a rapid pace. In order to simplify the process of drug delivery, eliminate costs and reduce the incidence of needlestick injuries, the pharmaceutical industry has shifted its focus towards the development of self-injection devices for parenteral drugs / therapies. This report specifically lays emphasis on the emergence of such patient-centric, convenient, cost-effective and user-friendly wearable injectors that are capable of administering large volumes of a drug subcutaneously in a home-care setting.
It is worth noting that the concept behind such injectors is being widely employed for the delivery of insulin. Over 15 such unique series of injectors (excluding variants) have already entered the market. On the other hand, there is only one large volume wearable injector (mentioned above) approved for the administration of a non-insulin biologic in the US. However, with a variety of biologics under investigation, we believe that device developers have a significant opportunity waiting to be tapped. The field is likely to pick up momentum in the next few years. In fact, an increase in the partnerships and investment activities demonstrate that the market is geared towards significant growth in the mid to long term.
One of the key objectives outlined for the study was to evaluate the future potential of the ongoing development programs of both big and small firms. Amongst other elements, the report elaborates on the following areas:
The study provides a detailed market forecast and opportunity analysis for the period between 2017 and 2027. The research, analysis and insights presented in this report include potential sales of the drug-device combinations that are being evaluated and are anticipated to enter the market in the next few years. To add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios. It is worth noting that, although the market of insulin delivery devices is relatively more mature, we have included a high-level opportunity analysis on the large volume wearable injectors being developed for delivery of insulin as well.
Our opinions and insights presented in this study were influenced by discussions conducted with several experts in this area. Specifically, we solicited the opinions of senior representatives including Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the large volume wearable injectors market.
Chapter 3 provides a general introduction to the market and highlights the growing demand for self-administration injection devices. The chapter lays emphasis on the need for such devices driven by the rising incidence of chronic diseases and emergency cases reported per day. Subsequently, it covers the different types of self-injection devices available in the market, highlighting their advantages. This section also features a brief discussion on the concerns related to needlestick injuries and emphasizes the growing preference for safe and easy-to-use devices.
Chapter 4 presents two separate lists of the large volume wearable injectors for insulin and the other biologics. In addition, the chapter includes a detailed analysis of both these lists based on the products’ status of development, device category (infusion pump / patch pump), type of dose (bolus / continuous) and the capacity of each device. Specifically for insulin delivery devices, we have identified whether the device is equipped with continuous glucose monitoring (CGM) monitoring or not.
Chapter 5 presents key takeaways from the market landscape of this emerging field. It features a comparison of product competitiveness and supplier power of each device in the form of a 2 x 2 matrix. In addition, the chapter includes a grid based representation of devices based on the target indication, status of development, type of dose (continuous / bolus / both) and type of device (patch pump / infusion pump). The chapter also provides an analysis of the patents granted / filed in this space over the last three years.
Chapter 6 presents detailed profiles on the large volume wearable injectors being developed for biologics / drugs other than insulin. The profiles include information about the developer of the device, device specifications and features, advantages, current status of development and related collaborations. We have presented such insights on 10 devices capable of delivering large dosage volumes.
Chapter 7 is focused on the devices developed / being developed for the administration of insulin. It presents information on diabetes, the most popular target indication, including information on its epidemiology and the evolution of insulin-delivery systems. Additionally, it includes detailed profiles on some of the large volume wearable devices developed / being developed for the delivery of insulin. Each profile covers information on the device developer, device specifications, advantages and the associated developments. The chapter also includes a social media analysis highlighting the popularity of these devices in the industry.
Chapter 8 provides detailed case studies on the drugs / therapies that are currently being evaluated with the devices mentioned in chapter 4. Each case study includes drug / therapy specifications, respective mechanisms of action, current status of development, information on the sales of each product, dosage and recent developments.
Chapter 9 presents a list of candidates (marketed / pipeline) that have the potential to be administered using large volume wearable injectors in the future. The likelihood of delivery of a molecule was estimated based on the volume of dose, mode of administration, frequency of administration, standard / weight-based dose and the chronicity of the target indication.
Chapter 10 provides projections of the future opportunity of the large volume wearable injectors market for biologics till 2027. It highlights the market size of such injectors (in terms of value) and the number of units that are likely to be sold within the forecast time period. We have clearly laid out the forecast methodology along with the key assumptions that were taken into consideration for estimating the market size.
Chapter 11 includes comprehensive profiles of the key companies that are active in this market. We have profiled companies ( presented in an alphabetical order ) developing devices for administration of insulin / other biologics. Each company profile includes a company overview, details on its financial performance, product portfolio and collaborations.
Chapter 12 provides a SWOT analysis, highlighting strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.
Chapter 13 summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the future of large volume wearable injectors market based on the research and analysis described in the previous chapters.
Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the insights provided to us by Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services).
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.
Chapter 16 is an appendix, which provides a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Delivery Devices
3.3. Self-Administration: An Emerging Trend
3.3.1. Rising Burden of Chronic Diseases
3.3.2. Need for Immediate Treatment in Emergency Situations
3.3.3. Expansion of Injectable Biologics Pipeline
3.3.4. Systems Available for Self-administration
3.3.4.1. Prefilled Syringes
3.3.4.2. Pen-Injectors
3.3.4.3. Autoinjectors
3.3.4.4. Needle-Free Injectors
3.3.4.5. Large Volume Wearable Injectors
3.3.5. Needlestick Injuries
3.3.5.1. Incidence and Cost Burden
3.3.5.2. Prevention of Needlestick Injuries
3.3.5.3. Government Legislations for the Prevention of Needlestick Injuries
3.4. Advantages and Future Prospects of Self-Injection Systems
4. LARGE VOLUME WEARABLE INJECTORS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Large Volume Wearable Injectors: Overall Development Landscape
4.3. Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
4.3.1. Distribution by Stage of Development
4.3.2. Distribution by Storage Capacity
4.3.3. Distribution by Device Category (Patch Pumps / Infusion Pumps)
4.3.4. Distribution by Type of Dose (Bolus / Continuous)
4.3.5. Distribution by Usability (Disposable / Reusable)
4.3.6. Distribution by Leading Players
4.4. Large Volume Wearable Injectors: Development Landscape for Insulin
4.4.1. Distribution by Stage of Development
4.4.2. Distribution by Device Volume
4.4.3. Distribution by Device Category (Patch Pumps / Infusion Pumps)
4.4.4. Distribution by Usability (Disposable / Reusable)
4.4.5. Distribution by Availability of CGM System
4.4.6. Distribution by Leading Players
4.5. Large Volume Wearable Injectors: Distribution by Geography
5. PRODUCT COMPETITIVENESS, CLINICAL DESIGN AND PATENT ANALYSIS
5.1. Chapter Overview
5.2. Product Competitiveness Analysis
5.2.1. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Biologics
5.2.2. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
5.3. Grid Analysis: Distribution of Large Volume Wearable Injectors Based on Development Phase and Type of Dosage
5.4. Patent Analysis: Large Volume Wearable Injectors, 2013-2016
5.4.1. Distribution by Current Status
5.4.2. Distribution by Year
5.4.3. Distribution by Key Players
5.4.4. Distribution by Regional Approving Authorities
5.4.5. Distribution by the Type of Patent
5.4.6. Distribution by Patent Expiry Year
6. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN BIOLOGICS: DEVICE PROFILES
6.1. Chapter Overview
6.2. eLVD Patch Pump (Elcam Drug Delivery Devices (E3D))
6.2.1. Introduction
6.2.2. Product Description
6.2.3. Advantages
6.3. Enable Injector (Enable Injections)
6.3.1. Introduction
6.3.2. Product Description
6.3.3. Usage
6.3.4. Advantages
6.3.5. Recent Developments
6.4. Lapas (Bespak)
6.4.1. Introduction
6.4.2. Product Description
6.4.3. Advantages
6.5. BD Libertas™ Wearable Injector (Becton Dickinson)
6.5.1. Introduction
6.5.2. Product Description
6.5.3. Usage
6.5.4. Advantages
6.6. PatchPump (SteadyMed Therapeutics)
6.6.1. Introduction
6.6.2. Product Description
6.6.3. Usage
6.6.4. Advantages
6.6.5. Recent Developments
6.7. Precision-Therapy™ Wearable Injector, Flex-Therapy™ Wearable Injector and Flex-Therapy™ Mini Wearable Injector (Unilife Corporation)
6.7.1. Introduction
6.7.2. Product Description
6.7.3. Usage
6.7.4. Advantages
6.7.5. Recent Developments
6.8. sc2™Wear Infusor (scPharmaceuticals)
6.8.1. Introduction
6.8.2. Product Description
6.8.3. Advantages
6.8.4. Recent Developments
6.9. Single-use Injection Device (Roche)
6.9.1. Introduction
6.9.2. Product Description
6.9.3. Usage
6.9.4. Advantages
6.9.5. Recent Developments
6.10. SenseBolus, SensePatch and SenseTrial (Sensile Medical)
6.10.1. Introduction
6.10.2. Product Description
6.10.3. Usage
6.10.4. Advantages
6.10.5. Recent Developments
6.11. SmartDose Electronic Wearable Injector (West Pharmaceutical Services)
6.11.1. Introduction
6.11.2. Product Description
6.11.3. Usage
6.11.4. Advantages
6.11.5. Recent Developments
7. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN: DEVICE PROFILES
7.1. Chapter Overview
7.2. Diabetes: An Introduction
7.2.1. Epidemiology
7.2.2. Available Therapies
7.2.3. Need for Diabetes Management Systems
7.3. Advanced Insulin Delivery Systems: Device Profiles
7.3.1. ACCU-CHEK (Roche Diagnostics)
7.3.1.1. Introduction
7.3.1.2. Product Information
7.3.1.3. Advantages
7.3.1.4. Recent Developments
7.3.2. DANA Diabecare Insulin Pumps (SOOIL)
7.3.2.1. Introduction
7.3.2.2. Product Information
7.3.2.3. Advantages
7.3.3. JewelPUMP™ I and JewelPUMP™ II (Debiotech)
7.3.3.1. Introduction
7.3.3.2. Product Information
7.3.3.3. Advantages
7.3.3.4. Recent Developments
7.3.4. MiniMed 530G (Medtronic)
7.3.4.1. Introduction
7.3.4.2. Product Information
7.3.4.3. Advantages
7.3.4.4. Recent Developments
7.3.5. mylife™ YpsoPump (Ypsomed)
7.3.5.1. Introduction
7.3.5.2. Product Information
7.3.5.3. Advantages
7.3.6. OmniPod (Insulet Corporation)
7.3.6.1. Introduction
7.3.6.2. Product Information
7.3.6.3. Advantages
7.3.6.4. Recent Developments
7.3.7. OneTouch Via™ (Johnson & Johnson)
7.3.7.1. Introduction
7.3.7.2. Product Information
7.3.7.3. Usage
7.3.7.4. Advantages
7.3.8. PAQ™ (CeQur)
7.3.8.1. Introduction
7.3.8.2. Product Information
7.3.8.3. Usage
7.3.8.4. Advantages
7.3.8.5. Recent Developments
7.3.9. t:flex (Tandem Diabetes Care)
7.3.9.1. Introduction
7.3.9.2. Product Information
7.3.9.3. Advantages
7.3.9.4. Recent Developments
7.4. Large Volume Wearable Injectors for Insulin: Trends on Social Media
7.4.1. Large Volume Wearable Injectors for Insulin: Twitter Trends
7.4.2. Large Volume Wearable Injectors for Insulin: Device Recalls
7.4.3. Large Volume Wearable Injectors for Insulin: Popularity of Continuous Glucose Monitoring
8. CASE STUDIES: DRUG-DEVICE COMBINATIONS UNDER EVALUATION
8.1. Chapter Overview
8.2. Repatha / Evolocumab / AMG 145
8.2.1. Drug Specifications
8.2.2. Mechanism of Action
8.2.3. Development History
8.2.4. Current Status of Development
8.2.5. Dosage and Sales Information
8.3. Treprostinil
8.3.1. Drug Specifications
8.3.2. Mechanism of Action
8.3.3. Development History
8.3.4. Current Status of Development
8.3.5. Dosage and Sales Information
8.4. Furosemide
8.4.1. Drug Specifications
8.4.2. Mechanism of Action
8.4.3. Development History
8.4.4. Current Status of Development
8.4.5. Dosage and Sales Information
8.5. Herceptin
8.5.1. Drug Specifications
8.5.2. Mechanism of Action
8.5.3. Development History
8.5.4. Current Status of Development
8.5.5. Dosage and Sales Information
8.6. ND0612 / Levadopa and Carbidopa
8.6.1. Drug Specifications
8.6.2. Mechanism of Action
8.6.3. Development History
8.6.4. Current Status of Development
8.6.5. Dosage and Sales Information
8.7. ND0701 / Apomorphine
8.7.1. Drug Specifications
8.7.2. Mechanism of Action
8.7.3. Current Status of Development
8.7.4. Dosage and Sales Information
8.8. SMT-201 / Ketorolac
8.8.1. Drug Specifications
8.8.2. Mechanism of Action
8.8.3. Development History
8.8.4. Current Status of Development
8.8.5. Dosage and Sales Information
8.9. Ceftriaxone
8.9.1. Drug Specifications
8.9.2. Mechanism of Action
8.9.3. Development History
8.9.4. Current Status of Development
8.9.5. Dosage and Sales Information
9. TARGET BIOLOGICS FOR LARGE VOLUME WEARABLE INJECTORS
9.1. Chapter Overview
9.2. Marketed Biologics
9.2.1. Marketed Biologics: Most Likely Candidates for Administration with Large Volume Wearable Injectors
9.2.2. Marketed Biologics: Likely Candidates for Administration with Large Volume Wearable Injectors
9.2.3. Marketed Biologics: Less Likely Candidates for Administration with Large Volume Wearable Injectors
9.3. Pipeline Molecules
9.3.1. Pipeline Molecules: Most Likely Candidates for Administration with Large Volume Wearable Injectors
9.3.2. Pipeline Molecules: Likely Candidates for Administration with Large Volume Wearable Injectors
9.3.3. Pipeline Molecules: Less Likely Candidates for Administration with Large Volume Wearable Injectors
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. Key Assumptions
10.4. Forecast Output
10.4.1. Large Volume Wearable Injectors Market for Non-Insulin Biologics, 2017-2027
10.4.2. Large Volume Wearable Injectors Market for Insulin, 2017-2027
11. LARGE VOLUME WEARABLE INJECTORS: KEY PLAYERS
11.1. Chapter Overview
11.2. Becton Dickinson
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Product Portfolio
11.2.4. Collaborations
11.2.5. Future Outlook
11.3. CeQur
11.3.1. Company Overview
11.3.2. Product Portfolio
11.3.3. Future Outlook
11.4. Debiotech
11.4.1. Company Overview
11.4.2. Product Portfolio
11.4.3. Collaborations
11.4.4. Future Outlook
11.5. Insulet Corporation
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Product Portfolio
11.5.4. Collaborations
11.5.5. Future Outlook
11.6. Roche Laboratories
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Product Portfolio
11.6.4. Collaborations
11.6.5. Future Outlook
11.7. Sensile Medical
11.7.1. Company Overview
11.7.2. Product Portfolio
11.7.3. Collaborations
11.7.4. Future Outlook
11.8. SteadyMed Therapeutics
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Product Portfolio
11.8.4. Collaborations
11.8.5. Future Outlook
11.9. Tandem Diabetes Care
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Product Portfolio
11.9.4. Collaborations
11.9.5. Future Outlook
11.10. Unilife Corporation
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Product Portfolio
11.10.4. Collaborations
11.10.5. Future Outlook
11.11. West Pharmaceutical Services
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Product Portfolio
11.11.4. Collaborations
11.11.5. Future Outlook
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
13. CONCLUSION
13.1. Novel Drug / Therapy Delivery Solutions Offer a number of Advantages, including Self-Administration in the Home-care Setting
13.2. Technical Improvements have Led to the Development of Advanced Large Volume Wearable Delivery Systems Having Multiple Useful Features
13.3. The Market, Characterized by the Presence of both Large and Small Companies, is Likely to be Impacted by the Growth of the Biologics Market
13.4. Partnerships and Venture Capital Financing have Emerged as Key Drivers of Growth in this Upcoming Area
13.5. The Large Volume Wearable Injector Market is Projected to Grow at an Aggressive Pace Over the Next Decade
13.6. Concluding Remarks
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Menachem Zucker, VP and Chief Scientist, Elcam Medical
14.3. Michael Hooven, CEO, Enable Injections
14.4. Ben Moga, President, Ratio Drug Delivery
14.5. Pieter Muntendam, President and CEO, scPharmaceuticals
14.6. Graham Reynolds, VP & GM, Global Biologics and Tiffany H. Burke, Director, Global Communications, West Pharmaceutical Services
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Types of Drug Delivery Systems
Figure 3.2 Types of Self-Injection Devices
Figure 3.3 Worldwide Evolution in Healthcare Safety Legislation
Figure 4.1 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Figure 4.2 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
Figure 4.3 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Figure 4.4 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose (Bolus / Continuous)
Figure 4.5 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability (Disposable / Reusable)
Figure 4.6 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Leading Players
Figure 4.7 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Figure 4.8 Large Volume Wearable Injectors for Insulin: Distribution by Device Volume
Figure 4.9 Large Volume Wearable Injectors for Insulin: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Figure 4.10 Large Volume Wearable Injectors for Insulin: Distribution by Usability (Disposable / Reusable)
Figure 4.11 Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
Figure 4.12 Large Volume Wearable Injectors for Insulin: Distribution by Leading Players
Figure 4.13 Large Volume Wearable Injectors: Distribution by Geography
Figure 4.14 Large Volume Wearable Injectors: Regional Landscape
Figure 5.1 Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Biologics
Figure 5.2 Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
Figure 5.3 Grid Analysis: Distribution by Stage of Development and Type of Dosage
Figure 5.4 Patent Analysis: Distribution by Current Status
Figure 5.5 Patent Analysis: Distribution by Year
Figure 5.6 Patent Analysis: Distribution by Key Players
Figure 5.7 Patent Analysis: Distribution by Regional Approving Authorities
Figure 5.8 Patent Analysis: Distribution by the Type of Patent
Figure 5.9 Patent Analysis: Distribution by Patent Expiry Year
Figure 7.1 Diabetes: Worldwide Distribution of the Patients (2015)
Figure 7.2 Prevalence of Diabetes: Distribution by Continent (In Million)
Figure 7.3 Insulin-Based Therapies for Diabetes
Figure 7.4 Non-Insulin Therapies for Diabetes
Figure 7.5 Large Volume Wearable Injectors for Insulin: Twitter Trends (2010-2015)
Figure 7.6 Large Volume Wearable Injectors for Insulin: Twitter Word Cloud (2010-2015)
Figure 7.7 Large Volume Wearable Injectors for Insulin: Device Recalls (2010-2015)
Figure 7.8 Large Volume Wearable Injectors for Insulin: Popularity of Continuous Glucose Monitoring
Figure 8.1 Treprostinil IV Formulation: Annual Sales 2012 - Q1-Q3 2016 (USD Million)
Figure 8.2 Furosemide IV Formulation: Annual Sales, 2013 - Q1-Q3 2016 (EUR Million)
Figure 8.3 Herceptin®: Annual Sales, 1999-2015 (CHF Million)
Figure 8.4 Levodopa / Carbidopa: Annual Sales, 2010-2015 (USD Million)
Figure 8.5 Apokyn®: Annual Sales, 2011-2015 (USD Million)
Figure 8.6 Rocephin®: Annual Sales, 2014-2015 (CHF Million)
Figure 9.1 Marketed / Under Development Molecules: Parameters and Scoring Criteria
Figure 10.1 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, 2017-2027 (USD Million)
Figure 10.2 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, Number of Units, 2017-2027 (Million)
Figure 10.3 Large Volume Wearable Injectors for Non-Insulin Biologics: Market Evolution 2021-2024-2027 (Million)
Figure 10.4 Large Volume Wearable Injectors for Non-Insulin Biologics: Market Share of Devices, 2016, 2020, 2027 (USD Million)
Figure 10.5 Large Volume Wearable Injectors Market for Insulin: Base Scenario, 2017-2027 (USD Million)
Figure 10.6 Large Volume Wearable Injectors Market for Insulin: Base Scenario, Number of Units, 2017-2027 (Million)
Figure 11.1 Becton Dickinson: Annual Revenues, 2011-2016 (USD Billion)
Figure 11.2 Insulet Corporation: Annual Revenues, 2011- Q1-Q3 2016 (USD Million)
Figure 11.3 Roche: Annual Revenues, 2011 - Q1-Q3 2016 (CHF Million)
Figure 11.4 Roche: Annual Revenues, 2016: Distribution by Business Segment (CHF Billion)
Figure 11.5 Tandem Diabetes Care: Annual Revenues, 2012 - Q1-Q3 2016 (USD Million)
Figure 11.6 Unilife Corporation: Annual Revenues, 2011-2016 (USD Million)
Figure 11.7 West Pharmaceutical Services: Annual Revenues, 2011-2016 (USD Million)
Figure 13.1 Large Volume Wearable Injectors for Non-Insulin Biologics Market Summary: Number of Units 2017, 2022 and 2027 (Million)
Table 3.1 List of Prefilled Syringes
Table 3.2 List of Pen-Injector Systems
Table 3.3 List of Autoinjector Systems
Table 3.4 List of Needle-Free Injectors
Table 4.1 Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
Table 4.2 Large Volume Wearable Injectors: Development Landscape for Insulin
Table 6.1 Large Volume Wearable Injectors for Non-Insulin Biologics: List of Devices Profiles
Table 7.1 Advanced Insulin Delivery Systems
Table 7.2 DANA Diabecare®: Specifications
Table 7.3 JewelPUMP™: Specifications
Table 7.4 JewelPUMP™: Advantages
Table 7.5 MiniMed® 530G: Specifications
Table 7.6 mylife™ YpsoPump®: Specifications
Table 7.7 OmniPod®: Specifications
Table 7.8 t:flex®: Specifications
Table 8.1 Large Volume Wearable Injectors: Drugs under Evaluation
Table 8.2 Repatha®: Clinical Trials
Table 8.3 Remodulin®: Dosage Regimen
Table 8.4 Orenitram®: Dosage
Table 8.5 Tyvaso®: Dosage
Table 8.6 Furosemide: Clinical Trials
Table 8.7 Furosemide: Manufacturers and Suppliers
Table 8.8 Subcutaneous Herceptin®: Clinical Trials
Table 8.9 ND0612: Clinical Trials
Table 8.10 ND0612H: Phase II Trials (Objectives and Results)
Table 8.11 Levodopa / Carbidopa: Manufacturer and Suppliers
Table 8.12 Ketorolac Tromethamine: Manufacturers and Suppliers
Table 9.1 Marketed Biologics: Most Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.2 Marketed Biologics: Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.3 Marketed Biologics: Less Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.4 Pipeline Molecules: Most Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.5 Pipeline Molecules: Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.6 Pipeline Molecules: Less Likely Candidates for Administration with Large Volume Wearable Injectors
Table 10.1 Large Volume Wearable Injectors for Non-Insulin Biologics (Approved / Under Development)
Table 11.1 Large Volume Wearable Injectors: Key Players
Table 11.2 Becton Dickinson: Medical Devices Portfolio
Table 11.3 Debiotech: Medical Devices Portfolio
Table 11.4 Sensile Medical: Medical Devices Portfolio
Table 11.5 SteadyMed Therapeutics: Medical Devices Portfolio
Table 11.6 t:slim X2™ Insulin Pump: Features
Table 11.7 t:slim X2™ Insulin Pump: Technical Specifications
Table 11.8 t:flex® Insulin Pump: Features
Table 11.9 t:flex® Insulin Pump: Technical Specifications
Table 11.10 West Pharmaceutical Services: Medical Devices Portfolio
Table 12.1 Large Volume Wearable Injectors: SWOT Analysis
Table 12.2 Recall of Device (Autoinjectors and Prefilled Syringes)
Table 15.1 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Table 15.2 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
Table 15.3 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Table 15.4 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose (Bolus / Continuous)
Table 15.5 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability (Disposable / Reusable)
Table 15.6 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Leading Players
Table 15.7 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Table 15.8 Large Volume Wearable Injectors for Insulin: Distribution by Device Volume
Table 15.9 Large Volume Wearable Injectors for Insulin: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Table 15.10 Large Volume Wearable Injectors for Insulin: Distribution by Usability (Disposable / Reusable)
Table 15.11 Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
Table 15.12 Large Volume Wearable Injectors for Insulin: Distribution by Leading Players
Table 15.13 Large Volume Wearable Injectors: Distribution by Geography
Table 15.14 List of Patents, 2013-2016
Table 15.15 Patent Analysis: Distribution by Current Status
Table 15.16 Patent Analysis: Distribution by Year
Table 15.17 Patent Analysis: Distribution by Key Players
Table 15.18 Patent Analysis: Distribution by Regional Approving Authorities
Table 15.19 Patent Analysis: Distribution by the Type of Patent
Table 15.20 Patent Analysis: Distribution by Patent Expiry Year
Table 15.21 Diabetes: Worldwide Distribution of the Patients (2015)
Table 15.22 Prevalence of Diabetes: Distribution by Continent (In Million)
Table 15.23 Treprostinil IV Formulation: Annual Sales, 2012 - Q1-Q3 2016 (USD Million)
Table 15.24 Furosemide IV Formulation: Annual Sales, 2013 - Q1-Q3 2016 (EUR Million)
Table 15.25 Herceptin®: Annual Sales, 1999-2015 (CHF Million)
Table 15.26 Levodopa / Carbidopa: Annual Sales, 2010-2015 (USD Million)
Table 15.27 Apokyn®: Annual Sales, 2011-2015 (USD Million)
Table 15.28 Rocephin®: Annual Sales, 2014-2015 (CHF Million)
Table 15.29 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, 2017-2027 (USD Million)
Table 15.30 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Conservative Scenario, 2017-2027 (USD Million)
Table 15.31 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Optimistic Scenario, 2017-2027 (USD Million)
Table 15.32 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, Number of Units, 2017-2027 (Million)
Table 15.33 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Conservative Scenario, Number of Units, 2017-2027 (Million)
Table 15.34 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Optimistic Scenario, Number of Units, 2017-2027 (Million)
Table 15.35 Large Volume Wearable Injectors for Non-Insulin Biologics: Market Evolution 2021-2024-2027 (Million)
Table 15.36 Large Volume Wearable Injectors for Non-Insulin Biologics: Market Share of Devices, 2016, 2020, 2027 (USD Million)
Table 15.37 Large Volume Wearable Injectors Market for Insulin: Base Scenario, 2017-2027 (USD Million)
Table 15.38 Large Volume Wearable Injectors Market for Insulin: Base Scenario, Number of Units, 2017-2027 (Million)
Table 15.39 Becton Dickinson: Annual Revenues, 2011-2016 (USD Billion)
Table 15.40 Insulet Corporation: Annual Revenues, 2011- Q1-Q3 2016 (USD Million)
Table 15.41 Roche: Annual Revenues, 2011 - Q1-Q3 2016 (CHF Million)
Table 15.42 Roche: Annual Revenues, 2016: Distribution by Business Segment (CHF Billion)
Table 15.43 Tandem Diabetes Care: Annual Revenues, 2012 - Q1-Q3 2016 (USD Million)
Table 15.44 Unilife Corporation: Annual Revenues, 2011-2016 (USD Million)
Table 15.45 West Pharmaceutical Services: Annual Revenues, 2011-2016 (USD Million)
Table 15.46 Large Volume Wearable Injectors for Non-Insulin Biologics Market Summary: Number of Units 2017, 2022 and 2027 (Million)
The following companies and organizations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES